title: Phospholipase C-gamma inhibition prevents EGF protection of intestinal cytoskeleton and barrier against oxidants.
abstract: Loss of intestinal barrier integrity is associated with oxidative inflammatory GI disorders including inflammatory bowel disease. Using monolayers of human intestinal epithelial (Caco-2) cells, we recently reported that epidermal growth factor (EGF) protects barrier integrity against oxidants by stabilizing the microtubule cytoskeleton, but the mechanism downstream of the EGF receptor (EGFR) is not established. We hypothesized that phospholipase C (PLC)-gamma is required. Caco-2 monolayers were exposed to oxidant (H2O2) with or without pretreatment with EGF or specific inhibitors of EGFR tyrosine kinase (AG-1478, tyrphostin 25) or of PLC (L-108, U-73122). Other Caco-2 cells were stably transfected with a dominant negative fragment for PLC-gamma (PLCz) to inhibit PLC-gamma activation. Doses of EGF that enhanced PLC activity also protected monolayers against oxidant-induced tubulin disassembly, disruption of the microtubule cytoskeleton, and barrier leakiness as assessed by radioimmunoassay, quantitative Western blots, high-resolution laser confocal microscopy, and fluorometry, respectively. Pretreatment with either type of inhibitor abolished EGF protection. Transfected cells also lost EGF protection and showed reduced PLC-gamma phosphorylation and activity. We conclude that EGF protection requires PLC-gamma signaling and that PLC-gamma may be a useful therapeutic target.
authors.affiliation: Division of Digestive Diseases, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois 60612, USA. ali_banan@rush.edu
authors.forename: A
authors.initials: A
authors.lastname: Banan
authors.forename: J Z
authors.initials: JZ
authors.lastname: Fields
authors.forename: Y
authors.initials: Y
authors.lastname: Zhang
authors.forename: A
authors.initials: A
authors.lastname: Keshavarzian
mesh_terms: D018938:Caco-2 Cells; D003599:Cytoskeleton / Q000187:drug effects / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D006861:Hydrogen Peroxide / Q000494:pharmacology*; D007413:Intestinal Mucosa / Q000502:physiology*; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000235:genetics; D008870:Microtubules / Q000378:metabolism; D009154:Mutation; D016877:Oxidants / Q000494:pharmacology*; D010539:Permeability; D051966:Phospholipase C gamma; D010766:Phosphorylation; D010738:Type C Phospholipases / Q000037:antagonists & inhibitors* / Q000235:genetics
chemical_list: D004791:Enzyme Inhibitors; D007527:Isoenzymes; D016877:Oxidants; D004815:Epidermal Growth Factor; D006861:Hydrogen Peroxide; D066246:ErbB Receptors; D010738:Type C Phospholipases; D051966:Phospholipase C gamma